AZD3199

DRUG5 trials

Sponsors

AstraZeneca

Conditions

Airway ObstructionAsthmaCOPDChronic Obstructive Pulmonary DiseaseHealthy VolunteersLung Disease

Phase 1

Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men

CompletedNCT00713271

AstraZenecaHealthy Volunteers

Start: 2008-08-31End: 2008-11-30Target: 27Updated: 2014-04-10

To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart

CompletedNCT01222442

AstraZenecaChronic Obstructive Pulmonary Disease, Lung Disease

Start: 2010-11-30End: 2011-02-28Updated: 2011-02-16

Phase 2

Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199

CompletedNCT00736489

AstraZenecaAirway Obstruction, Asthma

Start: 2008-08-31End: 2008-12-31Updated: 2014-05-19

Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients

CompletedNCT00929708

AstraZenecaCOPD

Start: 2009-06-30End: 2010-03-31Updated: 2014-02-17

Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma

CompletedNCT01348139

AstraZenecaAsthma

Start: 2011-05-31End: 2012-02-29Updated: 2013-03-05

Related Papers

Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β<sub>2</sub>-adrenoceptor agonist, with formoterol in patients with asthma

Therapeutic Advances in Respiratory Disease2013-08-013 citations

Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study.

2013-06-039 citations